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Abstract
Influenza viruses elude immune responses and antiviral chemotherapeutics through genetic drift and reassortment. As a result,
the development of new strategies that attack a highly conserved viral function to prevent and/or treat influenza infection is
being pursued.Such novel broadly acting antiviral therapies would beless susceptible to virus escapeand provide a long lasting
solution to the evolving virus challenge. Here we report the in vitro and in vivo activity of a human monoclonal antibody (A06)
against two isolates of the 2009 H1N1 pandemic influenza virus. This antibody, which was obtained from a combinatorial library
derived from a survivor of highly pathogenic H5N1 infection, neutralizes H5N1, seasonal H1N1and 2009 ‘‘Swine’’ H1N1pandemic
influenza in vitro with similar potency and is capable of preventing and treating 2009 H1N1 influenza infection in murine models
of disease. These resultsdemonstrate broadactivity of the A06 antibodyand its utility as an anti-influenza treatment option, even
against newly evolved influenza strains to which there is limited immunity in the general population.
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Introduction
Controlling the spread of influenza remains a major challenge
due to the unpredictable nature of the virus. Recently, a novel
human adapted H1N1 virus has emerged and progressed globally
such that the World Health Organization (WHO) has declared the
first influenza pandemic in 40 years [1,2]. Globally, efforts have
been undertaken to produce vaccines and stockpile small molecule
antiviral reserves to prevent and treat widespread influenza
disease. While these strategies are effective, they are not without
limitations. Vaccines have not provided lasting immunity against
influenza because of viral mutation (‘‘antigenic drift’’) and
reassortment (‘‘antigenic shift’’) [3,4,5,6]. Popular small molecule
antiviral treatments (oseltamivir) have recently lost effectiveness
due to the rapid proliferation of seasonal H1N1 strain resistanc,
demonstrating the urgent need to develop novel treatments for
influenza infection and disease.
Such new treatment options would ideally be both broadly
protective and provide a novel mechanism of attack against the virus.
Antibodies have very desirable properties as prophylactic and
therapeutic agents: long serum half-life, low immunogenicity and
high specificity for antigens. In addition, antibodies are currently
being used against infectious disease. For example, antibody clinical
prophylaxisagainstRSVisastandardofcareandantibodytherapyis
in development for treatment of anthrax [7,8,9,10]. A related passive
immunity strategy against influenza was used in the past during times
of crisis, and retrospective studies have quantified the benefits of such
strategies [11]. Furthermore, it would be beneficial for this agent to
act on a highly conserved site to increase its therapeutic lifespan.
Recently, work by us and others have described novel human
monoclonal antibodies capable of very broad heterotypic protection
that could be used in the treatment and prevention of influenza virus
infections [12,13,14]. Here we report in vitro neutralization and in vivo
efficacy in prophylactic and therapeutic mouse models of the novel
2009 H1N1 pandemic influenza virus infection by one such broadly
protective antibody derived from an H5N1 avian influenza survivor.
Methods
Antibody expression and purification
Human IgG1 antibody was expressed and purified essentially as
previously described [12].
Preparation of virus stocks
The A/California/04/2009 virus used in the microneutraliza-
tion studies is a recombinogenic virus composed of the
hemagglutinin (HA) and neuraminidase (NA) gene segments from
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segments are from A/PR/8/34 [15]. The recombinant virus was
propagated in MDCK cell culture. All other strains were amplified
in 10–11 day old embryonated hens’ eggs.
Microneutralization assay
Microneutralization assays were performed as previously
described [12]. Briefly, two-fold dilutions of mAb were incubated
with 100 TCID50 of virus for 1 h at 37uC prior to addition to
monolayers of MDCK cells. Cell monolayers were incubated for
72 h, and the presence of virus in supernatant was determined by
HA assay of duplicate samples. The neutralizing titer was defined
as the minimum inhibitory concentration at which the infectivity
of 100 TCID50 of the appropriate virus for MDCK cells was
completely neutralized in duplicate wells.
mAbs for prophylaxis and therapy in mice
Animal experiments were performed in accordance with the
guidelines of the Mount Sinai School of Medicine and St. Jude
Children’s Research Hospital Institutional Animal Care and Use
Committees (IACUC).
Female 6–8 weeks old Balb/C (Jackson Laboratories) or DBA/2
(Charles River) mice were housed 5–6 per cage in ABSL3+
containment. Food and water were provided ad libitum. For the
prophylactic studies, mice (5–6 per group, except where noted)
received 1, 2.5, 10, or 25 mg antibody A06 per kg of bodyweight
in approximately 200–300 mL of sterile phosphate-buffered saline
(PBS) by intraperitoneal (IP) injection. The control groups received
200–300 mL of 25 mg/kg non-immune human serum IgG (Sigma)
(n=3) or PBS by IP injection. Antibody was administered either
1 hour (Balb/C) or 24 hours (DBA/2) before being challenged
with A/California/04/09, which had been previously mouse-
adapted by 9 sequential lung passages, or wild-type A/Nether-
lands/602 virus. Mice were inoculated by intranasal administra-
tion of 3.3, 25, or 33 MLD50 (50% mouse lethal dose) influenza
virus in 30–50 mL of PBS. 2000 PFU (25 MLD50) of mouse-
adapted A/California/04/09 was used for infection of Balb/C
mice in the prophylactic and therapeutic studies, while 10 PFU
(3.3 MLD50) and 100 PFU (33 MLD50) was used for the A/
Netherlands/602 strain in DBA.2 mice. Symptoms preceding
death are weight loss .30% and general inactivity. Morbidity and
mortality were monitored either daily or at days 0, 3, 7, 10, and
14.
For therapeutic studies, Balb/C mice (10 per group) were given
a lethal virus dose of 25 MLD50 A/California/04/09 (2000 PFU)
followed by a single 15 mg/kg dose of antibody 24, 48, 72, 96,
120, or 144 hours post infection. Morbidity and mortality were
monitored for 17 days and the mice were weighed on days 0, 3, 7,
10, 14, and 17 following virus challenge. For dose escalation
studies, mice were given a viral dose of 3.3 MLD50 (10 PFU) A/
Netherlands/602/209 followed either 1 day or 2 days post
infection with a single IP injection of 2.5, 10 or 25 mg/kg dose of
antibody A06, vehicle (PBS), or non-immune IgG (25 mg/kg
dose). Morbidity and mortality were monitored for 14 days and
the mice were weighed daily following virus challenge.
All data for both the prophylactic and therapeutic studies was
plotted for days 3, 7, 10, 14, and 17 (where appropriate). Survival
data were plotted (Kaplan-Meier) and analyzed using the logrank
test to determine statistical significance (P,0.05). Mean weight
data were also plotted. All data were plotted and analyzed using
GraphPad Prism v.5.02 software.
2009 novel H1N1 predicted antibody binding site
sequence analysis
One thousand non-redundant 2009 novel H1N1 hemagglutinin
amino acid sequences deposited to the Influenza Sequence
Database [16] were aligned using MUSCLE v4 multiple sequence
alignment function accessible through the Influenza Sequence
Database website (http://www.ncbi.nlm.nih.gov/genomes/FLU/
FLU.html). Sequences were visually inspected for amino acid
changes within the predicted antibody binding site in the
hemagglutinin HA2 region described in [13,17]. Variants in both
the predicted contacting and non-contacting positions were noted
along with the frequency of occurrence.
Results
Pandemic H1N1 virus neutralization in vitro by antibody
A06
We previously reported the discovery of broadly neutralizing
antibodies from avian influenza survivor antibody libraries,
capable of mechanistically novel, heterosubtypic neutralization
against numerous H1N1 and H5N1 viruses [12]. Subsequent to
our publication, others have reported highly related and broadly
neutralizing human antibodies [13,14]. The novel unifying
mechanism these anti-hemagglutinin neutralizing antibodies
exhibit is that they do not inhibit virus-induced hemagglutination.
Structural analysis by both Sui et al. and Ekiert et al. have shown
the antibodies bind to the highly conserved stem of hemagglutinin
(HA) that prevents a conformational change required for viral host
cell fusion [13,17]. The reason these antibodies are broadly
neutralizing is attributed to the high sequence conservation of the
antibody epitope between H1, H5 and H9 type hemagglutinins,
which is coincidentally maintained in the newly emergent 2009
pandemic H1N1 strain (Table 1). From these collective observa-
tions, we predicted the 2009 pandemic H1N1 influenza would be
susceptible to neutralization by the previously described antibody
isolated from the Turkish avian influenza survivor libraries.
As a first step to test our prediction the A06 antibody (previously
referred to as mAb1 [12]) was tested in in vitro viral microneu-
tralization assays against a recombinogenic virus containing the
2009 H1N1 pandemic reference isolate A/California/04/2009
influenza virus (CA04) HA and neuraminidase (NA) proteins upon
a A/PR/8/34 based viral background, (hereafter referred to as A/
California/04/2009 6:2) [18]. In these assays the A06 antibody
demonstrated complete viral neutralization of the 2009 H1N1
virus at final concentrations as low as 10 mg/ml (Table 1), which is
in good agreement with neutralization results against other H5N1
and H1N1 strains that we have tested (Table 1).
Author Summary
Influenza viruses constantly challenge our ability to
prevent and treat their resulting infection. From a survivor
of the H5N1 influenza we have discovered an antibody
that is effective against both H5N1 and seasonal H1N1
influenza viruses. Here we show the antibody is effective
against 2009 pandemic influenza in a cell culture assay and
also in mouse models of disease when given before and
even after lethal influenza infection. The present work
demonstrates the viability of this particular antibody and
the general approach of using antibodies against viral
pathogens as opposed to traditional treatments that are
losing their efficacy for the prevention and treatment of
influenza infection. We conclude the efficacy of this
antibody warrants further experimental testing as an
alternative therapy for treatment in man.
Human mAb against Pandemic H1N1
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pandemic virus
To assess whether the A06 antibody could prevent or decrease
the severity of influenza infection in vivo, we performed a dose-
escalating study in a murine prophylactic model of disease. Briefly,
Balb/C mice were given a single IP dose of A06, infected
intranasally 1 hour later with 25MLD50 of a mouse-adapted CA04
H1N1 virus (see methods), and then monitored for survival and
body weight over the following 14 days (Figure 1A). In this study,
vehicle treated mice either died or were euthanized 6 to 10 days
post-infection and displayed pronounced progressive weight loss
during the course of infection. In sharp contrast, mice treated with
either 25 mg/kg or 10 mg/kg of A06 survived the lethal challenge
and regained lost weight by day 7. Survival in the 2.5 mg/kg
treatment group was 83%, with the mice losing more weight than
the higher dosed groups in the first 3 days post-infection, but still
regaining their pre-study weights by day 14. Survival in the 1 mg/
kg group was observed, but was the least prominent of all
treatment groups (33%) with the surviving mice losing body weight
through 10 days post-infection. Logrank test analysis of the
survival curves demonstrated statistical significance (P,0.0001).
These studies demonstrate antibody A06 is able to protect mice
from the lethality and weight loss associated with influenza virus
infection in a dose dependent manner.
To further support the previous results, we wanted to show
efficacy on a non-mouse- adapted novel human H1N1 strain as
well as assess efficacy against two different levels of viral challenge.
In the subsequent prophylaxis study, we used a novel H1N1
influenza strain A/Netherlands/602/2009 (Netherlands602) in the
more sensitive and susceptible DBA/2 mouse strain at both
3.3MLD50 (Figure 1B) and 33MLD50 (Figure 1C). In the
3.3MLD50 challenged study, mice treated with vehicle died or
were euthanized between 7 and 9 days post infection and
displayed pronounced progressive weight loss during the course
of infection. Antibody A06 administration provided significant
survival (P,0.0001) and considerable body weight maintenance
benefits. Specifically, mice challenged with 3.3MLD50 Nether-
lands602 in both the 25 mg/kg and 10 mg/kg dose groups
survived and lost some weight through day 7 that was rapidly
regained to their pre-study levels by day 10. Survival in the
2.5 mg/kg treatment group was 80% with greater weight loss
observed compared to the higher dosed groups.
In the subsequent DBA/2 study where mice were challenged
with 10 times more virus (33MLD50) than the previous A06
antibody treated groups they also displayed significant survival
(P,0.0001)and substantial body weight maintenance benefits
compared to controls. Specifically, the mice manifested disease
and mortality more rapidly than those in the 3.3MLD50 challenge
study, as both groups treated with PBS or non-immune IgG died
or were euthanized between 6 and 7 days post infection. In
contrast, all mice treated with 25 mg/kg of antibody A06 survived,
whereas those treated with 10 mg/kg or 2.5 mg/kg of A06 had an
80% survival rate. The average body weight of all the treated
groups declined through the first 7 days post-infection, but was
restored to pre-study levels by day 10. In summary, prophylactic
administration of antibody A06 appeared beneficial in abrogating
influenza-mediated weight loss, allowing faster recovery of infected
animals.
Therapeutic activity of antibody A06 in 2009 pandemic
H1N1 infection
Passive immunity may provide both prophylactic and thera-
peutic benefits against influenza infection. To address whether the
A06 antibody is therapeutically effective following infection, we
treated groups of CA04-infected Balb/C mice (25MLD50
infectious titer) with a single 15 mg/kg dose of antibody A06 at
1, 2, 3, 4, 5, or 6 days post-infection. All mice dosed 1 day after
infection survived, 90% of mice dosed 2 days after infection
survived, and 50% of the mice dosed 3 days after infection
survived. All mice dosed 4 days post infection and later either died
or were euthanized between days 7 and 10. Weight loss in the
therapeutic study was more severe than seen in the mice treated
prophylactically and similar to the vehicle-treated mice in the
prophylaxis study. All mice in this study lost ,30% of their body
weight due to the established novel H1N1 infection (Figure 2B)
and earlier treatment appeared linked to higher study end weights
and survival (Figure 2A and B). These results demonstrate the
utility of a therapeutic passive immunity approach against an
emergent strain of influenza and extend previous findings that
Table 1. The A-helix epitope targeted by the A06 antibody is highly conserved across numerous types of influenza.
Subtype Strain 18 19 20 21 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 MIC
Novel H1N1 A/California/04/2009 6:2 V D G W S T Q N A I D E I T N K V N S V I ,10
H1N1 A/South Carolina 1918 I - - - - - - - - - - G - - - - - - - - - ND
A/Puerto Rico/8/34 I - - - - - - - - - N G - - - - - - T - - 62-125
A/New Caledonia/20/99 - - - - - - - - - - N G - - - - - - - - - 9*
A/Solomon Islands/3/2006 - - - - - - - - - - N G - - - - - - - - - 83
A/Brisbane/59/2007 - - - - - - - - - - N G - - - - - - - - - 24
A/Texas/36/1991 I - - - - - - - - - N G - - - - - - - - - 250
H5N1 A/Indonesia/5/05 - - - - - - - K - - - G V - - - - - - I - 9*
A/Vietnam/1203/04 - - - - - - - K - - - G V - - - - - - I - 11*
A / E g y p t / 1 4 7 2 5 / 0 6 -------K ---G V ------I-2 *
A/Turkey/65596/2006 - - - - - - - K - - - G V - - - - - - I - 9*
H9N2 A/Hong Kong/1073/99 - A - - - - - K - - - K - - S - - - N I V ND
A-helix epitope sequences from novel H1N1, current and past seasonal isolates of H1N1, H5N1 and avian H9N2 hemagglutinin proteins were aligned. Positions are
labeledaccordingto HA2 numbering. Aminoacids atpositions 19-21, 41, 42, 45, 46, 49, 52, 53and 56are antibody contact points [13,17].The column onthefar right indicates
in vitro microneutralization minimal inhibitory concentrations (MIC) of antibody A06 in mg/ml for the isolates tested (ND=not done, *=previously reported data [8]).
doi:10.1371/journal.ppat.1000990.t001
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of influenza prophylaxis and therapy.
As a significant benefit in overcoming influenza infection was
seen in treatment groups administered A06 antibody at 1 or 2 days
post infection, our next study expanded the analysis at these times
through a dose escalation study. Specifically, we administered the
A06 antibody at 2.5, 10, and 25 mg/kg either 1 day (Figure 3A) or
2 days (Figure 3B) after infection with 3.3MLD50 of the
Netherlands602 strain of the 2009 pandemic H1N1 virus in
DBA/2 mice. As seen previously, PBS vehicle treated mice died or
were euthanized by 9 days post infection and displayed
pronounced progressive weight loss during the course of infection.
However, mice receiving 25 mg/kg or 10 mg/kg doses of
antibody A06, either at 1 day and 2 days post infection, survived
the Netherland602 virus infection, corroborating results found
with the CA04 viral challenge (Figure 3A and 3B, left panels).
Importantly, the lowest antibody dose (2.5 mg/kg) was sufficient to
overcome infection in all except one animal. As a benefit the
treated mice also gained weight after treatment with A06, arriving
at their pre-study weight by day 14 (Figure 3A and 3B, right
panels). In summary, our results demonstrate that antibody A06 is
a very effective treatment following novel H1N1 infection, even at
doses of 2.5 mg/kg in two different mouse models of influenza
infection and treatment.
Conservation of the predicted antibody epitope in novel
H1N1 isolates
Broadly active anti-influenza agents need to target essential sites
that are minimally prone to mutation. As a predictive assessment
of the potential efficacy of the A06 antibody against current H1N1
Figure 1. Antibody A06 prophylaxis protects mice from a lethal 2009 pandemic H1N1 influenza virus challenge. (A) Balb/C mice (n=6
except where noted) were challenged with 25MLD50 of a mouse-adapted 2009 H1N1 pandemic influenza A/California/04/2009 reference isolate
1 hour after a single interperitoneal injection of the indicated dose of A06 antibody. Survival (left panel) and weight (right panel) were monitored
over a 14 day period. Open blue squares- 25 mg/kg antibody A06, open red circles- 10 mg/kg antibody A06 (n=5), open green triangles- 2.5 mg/kg
antibody A06, open orange triangles- 1 mg/kg antibody A06, and black filled circles- PBS vehicle control. (B) and (C) DBA/2 mice (n=5 except where
noted) were challenged with either 3.3MLD50 (B) or 33MLD50 (C) A/Netherlands/602/2009 H1N1 pandemic influenza reference isolate 24 hours after
a single interperitoneal injection of the indicated dose of antibody A06. Survival (left panel) and weight (right panel) were monitored over 13 days
post-infection. Open blue squares- 25 mg/kg antibody A06, open red circles- 10 mg/kg antibody A06, open green triangles- 2.5 mg/kg antibody A06,
black filled circles- PBS vehicle control, open orange diamonds- 25 mg/kg human IgG control (n=3).
doi:10.1371/journal.ppat.1000990.g001
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hemagglutinin protein sequences within the proposed A-helix
epitope [13,17] for genetic drift. From the analysis of 1000 full
length hemagglutinin protein sequences (NCBI Influenza Virus
Resource November 11, 2009) [16], we found only 5 isolates that
varied from CA04 reference strain at three positions in the
proposed A-helix antibody epitope on the HA2 subunit (Table 2).
Only one of the five isolates (Canada-NS/RV1535/2009)
contained a mutation to a proposed contact point, which was a
conservative substitution of valine for isoleucine at residue 56. It is
significant to point out that isoleucine is found at an analogous
position in the H9N2 Hong Kong/1073/99 which is recognized
by the A06 antibody (Table 1 and unpublished data), suggesting
the isolate would still be susceptible to the A06 antibody. Three of
the remaining four mutations occurred at the non-contacting
residue 43, where lysine, serine, or aspartic acid was found instead
of asparagine. The final mutation was a proline replacement for
alanine non-contacting position 44. In summary, the analysis
suggests the isolates display limited allowances for genetic drift
within this region that may maintain susceptibility to A06.
Figure 2. Antibody A06 therapy protects Balb/C mice from death by 2009 pandemic H1N1 influenza infection. Balb/C (n=10, except
groups 4dpi and PBS where n=9) were infected with 25MLD50 A/California/04/2009. A single administration of 15 mg/kg per group was given 1–6
days post-infection. Open blue squares- 1 day post infection, open red circles- 2 days post- infection, open green triangles- 3 days post-infection,
filled triangles- 4 days post- infection, filled diamonds- 5 days post-infection, open black circles- 6 days post- infection, and open black squares- PBS
vehicle 1 day post-infection. Survival (left panel) and weight (right panel) were monitored for 17 days after infection.
doi:10.1371/journal.ppat.1000990.g002
Figure 3. Antibody A06 therapy protects DBA/2 mice from death by 2009 pandemic H1N1 influenza infection. DBA/2 mice were
infected with 3.3MLD50 of A/Netherlands/602/2009 and treated with a single administration of antibody A06 1 day (A) or 2 days (B) post-infection.
Three different A06 concentrations were tested along with vehicle (PBS) and non-specific IgG controls. Animals were monitored for survival (left
panels) and weight (right panels) over a 14 day period. Treatment groups (n=5) are labeled as in Figure1B and 2C. Open blue squares- 25 mg/kg
antibody A06, open red circles- 10 mg/kg antibody A06, open green triangles- 2.5 mg/kg antibody A06, black filled circles- PBS vehicle control, open
orange diamonds- 25 mg/kg human IgG control.
doi:10.1371/journal.ppat.1000990.g003
Human mAb against Pandemic H1N1
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We previously demonstrated, in vitro, that the A06 antibody
neutralizes a broad range of seasonal H1N1 and avian H5N1
influenza viruses causing human disease. In this study, we extend
these results and demonstrate that the A06 antibody is able to
protect from and treat the antigenically distinct 2009 pandemic
H1N1 virus infection in mouse models and also neutralize the
current seasonal H1N1 Brisbane/59/2007 strain in vitro. These
results provide further evidence for the use of passive immunity as
a weapon against influenza infection.
Passive immunity offers several benefits in comparison to
current chemotherapeutic anti-viral treatment options. First,
passive immunity provides the opportunity to protect at-risk
individuals from infection. At-risk segments of the population
include those who do not mount an immune response to vaccine,
the immunocompromised, those in poor health, pregnant women,
and those in critical care. The potential for long-lasting protection
arising from a single injection of antibodies such as A06 is
appealing. In addition, while orally available drugs are desirable to
reach a larger patient population and increase patient compliance
in courses of treatment, their use in critical care settings involving
the later stages of disease is limited by the route of administration.
Quite simply, injectable therapies are needed for patients that are
unable to receive orally administered anti-influenza treatment.
Current anti-viral treatments provide ease of use and therapeu-
tic benefit early in the course of infection. However, they suffer
from several limitations, namely high rates of resistance, as
exhibited recently in the seasonal H1N1 virus [19]. The
unexpected speed at which the H274Y mutation conferring
oseltamivir resistance took over as the dominant strain in the
2007–2008 influenza season demonstrates the challenges facing
widespread use of anti-viral agents targeting the neuraminidase
protein [3,19,20]. Antibodies such as A06 that attack a highly
conserved region of the hemagglutinin protein and not the
mutagenic hot spots near the receptor binding domain or the
neuraminidase protein may face fewer challenges arising from
mutation. Using the method of Caton, et al [21], we have not been
able to generate escape mutants after multiple attempts using the
A06 antibody on both H1N1 and H5N1 influenza strains,
suggesting that A06 is attacking a conserved, susceptible portion
of the virus (JS, unpublished results). Furthermore, conservation of
the predicted antibody binding site in the 2009 pandemic strain
isolates demonstrates the epitope has not changed significantly
from the time of its emergence in March 2009. It is likely the
ability to tolerate change in the hemagglutinin A-helix/fusion
peptide region may be highly restricted due to functional
constraints, as evidenced by the maintenance of this epitope
across numerous influenza sub-types.
However, an alternative interpretation to this observation is that
the region has not been sufficiently pressured to change and may
mutate when subjected to greater selective pressure, even though
we have not seen it yet in escape mutant analysis. Nevertheless,
even if escape were possible, passive immunization would likely be
highly effective when used in conjunction with other established
therapies to reduce the prospect of viral escape or resistance.
Here we have presented A06 antibody in vitro neutralization
results with numerous H1N1 and H5N1 strains from each sub-
type. Though recent H1N1 strains were neutralized with similar
antibody concentrations, two older strains, A/PR/8/34 and A/
Texas/1991, required substantially higher amounts of antibody to
be effective. Upon further sequence examination of these two
recent strains we have observed potential N-linked glycosylation
sites proximal to the predicted epitope in A/PR/8/34 (amino
acids 285–287) and A/Texas/1991 (amino acids 286–288). It is
possible that glycosylation at theses sites sterically hinders the
antibody and reduces its efficacy in this in vitro system. Further
testing will need to be performed both in vitro and in vivo to evaluate
the relevance of such a potential glycosylation site. Still, all H5N1
strains tested, representing all major clades of highly pathogenic
avian influenza, were effectively neutralized by antibody A06.
Considering the ability of the antibody to neutralize the novel
H1N1 virus, multiple seasonal H1N1 isolates, isolates from all
clades of human H5N1, and that the proposed epitope is highly
conserved amongst the initial sampling of one thousand reported
novel H1N1 hemagglutinin isolates, we predict that A06 will be
active against influenza strains bearing this epitope.
Additional testing is required to determine the efficacy and
utility of passive immunity in man. However, the profile of the A06
antibody and other broadly protective antibodies warrants their
testing in man. Success of such antibodies would justify their use in
cases of local, national, and global crisis. In addition, injectable
administration of antibodies such as A06 could protect critical care
patients unable to receive orally- administered anti-viral therapy.
Use of passive immune therapy in an integrative approach with
anti-viral chemotherapeutics could even decrease the frequency
and speed at which resistance to either agent is generated.
Furthermore, as these types of antibodies were found in large
survivor, vaccinee, and naı ¨ve donor combinatorial antibody
libraries, it suggests the mode of activity is immunologically
relevant. As a result, these broadly reactive anti-fusion antibodies
and their protective mechanisms should also be used as an
additional guide in the production and assessment of all future
influenza vaccines.
Table 2. Sequence analysis of novel H1N1 HA isolates shows limited variation in the predicted neutralization epitope.
Accession Strain 18 19 20 21 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 Frequency
ACS45035 A/California/04/2009 V D G W S T Q N A I D E I T N K V N S V I 98.70%
ACS34967 A/Sakai/2/2009 - - - - - - - K - - - - - - - - - - - - - 0.30%
ACY46863 A/Singapore/GP2687/2009 - - - - - - - S - - - - - - - - - - - - - 0.20%
ACY26192 A/Malaysia/820/2009 - - - - - - - D - - - - - - - - - - - - - 0.10%
ACV67229 A/Utah/06/2009 - - - - - - - - P - - - - - - - - - - - - 0.10%
ACQ73385 A/Canada-NS/RV1535/2009 - - - - - - - - - - - - - - - - - - - - V 0.60%
Alignment of hemagglutinin protein from novel H1N1 isolates deposited in the NCBI Influenza Virus Resource was performed using the multiple sequence alignment
application within the database. 1000 full length HA sequences contained in the database on November 11, 2009 were analyzed for variation in HA2 residues previously
shown to be contacted by neutralizing antibodies binding to the stem region [13,17].
doi:10.1371/journal.ppat.1000990.t002
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